摘要
目的评价泰素及泰素帝加顺铂方案治疗非小细胞肺癌的疗效和不良反应。方法将28例非小细胞肺癌,随机分组,泰素加顺铂(TP)组14例,泰素帝联合顺铂(DP)组14例,化疗3个周期后评价疗效和不良反应。结果TP组有效率为42.9%,DP组有效率为57.1%,无显著性差异(P>0.05);TP组中位生存期为13个月,1年生存率为48%,DP组中位生存期为14个月,1年生存率为53%,均无显著性差异(P>0.05),主要不良反应为骨髓抑制、消化道反应和脱发。TP组和DP组中性粒细胞减少发生率分别为42.9%(6/14)、85.7%(12/14),两者比较有显著性差异(P<0.05)。两组均无化疗相关死亡和体液潴留病例。结论DP方案疗效与TP方案相当,患者均能耐受,DP组的骨髓毒性较TP组重,其他主要不良反应相近。
Objective To estimate the efficacy and side effects of combined chemotherapy of paclitaxel or docetaxel plus cisplatin （TP or DP） in the treatment of non-small cell lung cancer （NSCLC）. Methods 28 patients with NSCLC diagnosed by pathology or cytology were enrolled into groups. The TP group with 14 patients received paclitaxel plus cisplatin and the DP group with another 14 patients received docetaxel plus cisplatin. Both regimens had 21 day one cycle, three weeks repeated. The efficacy and the side effects were evaluated after 3 cycles of chemotherapy. Results The efficacy could be estimated in 28 patients. The overall response rate （CR ＋ PR） was 42.9 % in the TP group and 57.1% in the DP group, respectively, there was no significant statistical difference （P 〉 0.05）. Median survival time was 13 months in the TP group and 14 months in the DP group, respectively; 1 year survival rate was 48 % in the TP group and 53 % in the DP group, respectively, There was no significant statistical difference （P 〉 0.05）. The major side effect of two groups were myelosuppression, gastrointestinal reactions and alopecia. The incidence of neutropenia in DP group was more severe than in TP group （85.7 % vs 42.9 %）. There was significant statistical difference （P 〈 0.05）. There was no chemotherapy related death and fluid retention. Conclusion Both TP and DP combined chemotherapy produce the similar efficacy and were tolerated. The myeiosuppression in DP group was more severe than in TP group, the other major side effects were similar in two groups.
出处
《实用癌症杂志》
2006年第5期506-508,共3页
The Practical Journal of Cancer
关键词
非小细胞肺癌
泰素
泰素帝
顺氯氨铂
联合化疗
Non-small cell lung cancer （NSCLC）
Paclitaxel
Docetaxel
Cisplatin
Combined chemotherapy
